Rexahn Pharmaceuticals, Inc. (RNN) Announces Publication on the Anti-Tumor Activity of Novel Anticancer Compound RX-8243

  @ibtimes on

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs, recently announced that a research article on the anti-tumor activity of RX-8243 and its analogues has been published in Bioorganic & Medicinal Chemistry Letters.

The article suggests that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells. The study demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, which suggests that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.

Chang Ahn, chief executive officer of Rexahn Pharmaceuticals, Inc., stated, “We are encouraged by the results of this study of RX-8243, which shows the potent anti-tumor properties of this unique compound. The study clearly demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, suggesting that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.”

For more information, please visit www.rexahn.com.

Join the Discussion
Nintendo's Newest Kirby Game Is A Total Detour
Nintendo's Newest Kirby Game Is A Total Detour
Fitbit's First Activity Watch Falls Short
Fitbit's First Activity Watch Falls Short
Dying Light Is The Spiritual Successor To 'Dead Island'
Dying Light Is The Spiritual Successor To 'Dead Island'
The Last Mitsubishi Evolution
The Last Mitsubishi Evolution
The i8 Is Proof BMW Should Make More Mid-Engined Cars
The i8 Is Proof BMW Should Make More Mid-Engined Cars
QD Vision Shows Off Cheap 4K TVs
QD Vision Shows Off Cheap 4K TVs

More Video